Sukhdev Chatu1, Sonia Saxena2, Venkataraman Subramanian3, Vasa Curcin4, Ghasem Yadegarfar2, Laura Gunn5, Azeem Majeed2, Richard C G Pollok1. 1. Department of Gastroenterology, St George's University Hospital, London, UK. 2. Department of Primary Care and Public Health, Imperial College, London, UK. 3. Department of Gastroenterology, St James's University Hospital, Leeds, UK. 4. Department of Computing, Imperial College, London, UK. 5. 1] Department of Primary Care and Public Health, Imperial College, London, UK [2] Stetson University, Integrative Health Science, DeLand, Florida, USA.
Abstract
OBJECTIVES: The efficacy of thiopurines (TPs) in altering the risk of surgery in Crohn's disease (CD) remains controversial. We evaluated the impact of TP therapy, optimal timing, and duration of TP therapy on first intestinal resection rates using a population-based cohort. METHODS: We constructed a population-based cohort of incident cases of CD between 1989 and 2005. We used the Kaplan-Meier analysis to calculate time trends in TP use and first intestinal resection in three groups defined by time period of diagnosis: 1989-1993, 1994-1999, and 2000-2005 groups A, B, and C, respectively. We quantified impact of duration and timing of TP treatment on likelihood of surgery using Cox regression and propensity score matching. RESULTS: We identified 5,640 eligible patients with CD. The 5-year cumulative probability of TP use increased from 12, 18, to 25% ( P<0.0001) while probability of first intestinal resection decreased from 15, 12 to 9% (P<0.001) in groups A, B, and C, respectively. Patients treated with at least 6 months of TP therapy had a 44% reduction in the risk of surgery (hazards ratio (HR): 0.56; 95% confidence interval (CI): 0.37-0.85) and those receiving at least 12 months of TP therapy had a 69% reduction in the risk of surgery (HR: 0.31; 95% CI: 0.22-0.44). Early treatment (<12 months from diagnosis) vs. late treatment with TP showed no additional benefit in reducing risk of surgery (HR: 0.41; 95% CI: 0.27-0.61 vs. 0.21; 95% CI: 0.13-0.34). CONCLUSIONS: Over the past 20 years, TP use has doubled, whereas intestinal surgery has fallen by one-third among the UK population of Crohn's patients. Prolonged exposure is associated with a reduced likelihood of surgery whereby more than 12 months TP therapy reduces the risk of first intestinal surgery two-fold; however, early initiation of TP treatment offered no apparent additional benefit.
OBJECTIVES: The efficacy of thiopurines (TPs) in altering the risk of surgery in Crohn's disease (CD) remains controversial. We evaluated the impact of TP therapy, optimal timing, and duration of TP therapy on first intestinal resection rates using a population-based cohort. METHODS: We constructed a population-based cohort of incident cases of CD between 1989 and 2005. We used the Kaplan-Meier analysis to calculate time trends in TP use and first intestinal resection in three groups defined by time period of diagnosis: 1989-1993, 1994-1999, and 2000-2005 groups A, B, and C, respectively. We quantified impact of duration and timing of TP treatment on likelihood of surgery using Cox regression and propensity score matching. RESULTS: We identified 5,640 eligible patients with CD. The 5-year cumulative probability of TP use increased from 12, 18, to 25% ( P<0.0001) while probability of first intestinal resection decreased from 15, 12 to 9% (P<0.001) in groups A, B, and C, respectively. Patients treated with at least 6 months of TP therapy had a 44% reduction in the risk of surgery (hazards ratio (HR): 0.56; 95% confidence interval (CI): 0.37-0.85) and those receiving at least 12 months of TP therapy had a 69% reduction in the risk of surgery (HR: 0.31; 95% CI: 0.22-0.44). Early treatment (<12 months from diagnosis) vs. late treatment with TP showed no additional benefit in reducing risk of surgery (HR: 0.41; 95% CI: 0.27-0.61 vs. 0.21; 95% CI: 0.13-0.34). CONCLUSIONS: Over the past 20 years, TP use has doubled, whereas intestinal surgery has fallen by one-third among the UK population of Crohn's patients. Prolonged exposure is associated with a reduced likelihood of surgery whereby more than 12 months TP therapy reduces the risk of first intestinal surgery two-fold; however, early initiation of TP treatment offered no apparent additional benefit.
Authors: James Irwin; Anton Lord; Emma Ferguson; Lisa A Simms; Katherine Hanigan; Carlos A Montoya; Graham Radford-Smith Journal: Dig Dis Sci Date: 2022-09-20 Impact factor: 3.487
Authors: Jonas Zeitz; Nicolas Fournier; Christian Labenz; Luc Biedermann; Pascal Frei; Benjamin Misselwitz; Sylvie Scharl; Stephan R Vavricka; Michael C Sulz; Michael Fried; Gerhard Rogler; Michael Scharl Journal: Inflamm Intest Dis Date: 2017-02-25
Authors: Fernando Mendonça Vidigal; Gláucio Silva de Souza; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Maria Cristina Vasconcellos Furtado; Antonio Carlos Santana Castro; André Luis Tavares Pinto; Bruno do Valle Pinheiro; Fabio Heleno de Lima Pace; Juliano Machado de Oliveira; Karine Andrade de Oliveira Zanini; Pedro Duarte Gaburri; Alexandre Zanini; Luiz Cláudio Ribeiro; Julio Maria Fonseca Chebli Journal: Med Sci Monit Date: 2014-11-05
Authors: Paulo Gustavo Kotze; Daniela Oliveira Magro; Barbara Saab; Mansur Paulo Saab; Lilian Vital Pinheiro; Marcia Olandoski; Maria de Lourdes Setsuko Ayrizono; Carlos Augusto Real Martinez; Claudio Saddy Rodrigues Coy Journal: Intest Res Date: 2018-01-18
Authors: Christopher Ma; Gordon W Moran; Eric I Benchimol; Laura E Targownik; Steven J Heitman; James N Hubbard; Cynthia H Seow; Kerri L Novak; Subrata Ghosh; Remo Panaccione; Gilaad G Kaplan Journal: Am J Gastroenterol Date: 2017-10-31 Impact factor: 10.864
Authors: Lester Tsai; Christopher Ma; Parambir S Dulai; Larry J Prokop; Samuel Eisenstein; Sonia L Ramamoorthy; Brian G Feagan; Vipul Jairath; William J Sandborn; Siddharth Singh Journal: Clin Gastroenterol Hepatol Date: 2020-10-27 Impact factor: 13.576